Potential policy reforms to strengthen the accelerated approval pathway
The accelerated approval pathway for new drugs in the United States is often praised but faces growing criticism of whether it is finding the appropriate balance between uncertainty, access and cost. To support efforts to strengthen the pathway, this paper provides an analysis of key concerns and the advantages and disadvantages of ten potential policy reforms - those achievable through the US FDA action alone, and those that would require a combination of government, payer and life science industry actions. Accelerated approval sits at the heart of many of the controversies regarding drug approvals and pricing, and this analysis provides perspectives on how best to strengthen the pathway within the broader landscape of an innovative US healthcare system.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of comparative effectiveness research - 10(2021), 16 vom: 02. Nov., Seite 1177-1186 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaltenboeck, Anna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Accelerated approval pathway |
|---|
| Anmerkungen: |
Date Completed 03.12.2021 Date Revised 14.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/cer-2021-0184 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329703722 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329703722 | ||
| 003 | DE-627 | ||
| 005 | 20231225205705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/cer-2021-0184 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1098.xml |
| 035 | |a (DE-627)NLM329703722 | ||
| 035 | |a (NLM)34427103 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kaltenboeck, Anna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potential policy reforms to strengthen the accelerated approval pathway |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The accelerated approval pathway for new drugs in the United States is often praised but faces growing criticism of whether it is finding the appropriate balance between uncertainty, access and cost. To support efforts to strengthen the pathway, this paper provides an analysis of key concerns and the advantages and disadvantages of ten potential policy reforms - those achievable through the US FDA action alone, and those that would require a combination of government, payer and life science industry actions. Accelerated approval sits at the heart of many of the controversies regarding drug approvals and pricing, and this analysis provides perspectives on how best to strengthen the pathway within the broader landscape of an innovative US healthcare system | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a FDA | |
| 650 | 4 | |a accelerated approval pathway | |
| 650 | 4 | |a access | |
| 650 | 4 | |a cost | |
| 650 | 4 | |a innovation | |
| 650 | 4 | |a policy reforms | |
| 650 | 4 | |a surrogate endpoints | |
| 650 | 4 | |a uncertainty | |
| 700 | 1 | |a Mehlman, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Pearson, Steven D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of comparative effectiveness research |d 2012 |g 10(2021), 16 vom: 02. Nov., Seite 1177-1186 |w (DE-627)NLM218708033 |x 2042-6313 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:16 |g day:02 |g month:11 |g pages:1177-1186 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/cer-2021-0184 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 16 |b 02 |c 11 |h 1177-1186 | ||